Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial

WX-0593 (Iruplinalkib) is a novel, highly selective oral ALK and ROS1 tyrosine kinase inhibitor (TKI). In this study, the safety, antitumor activity, and pharmacokinetics of WX-0593 were evaluated in advanced non-small cell lung cancer (NSCLC) patients with ALK or ROS1 rearrangement. In the dose-esc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Fang, Jian, Hao, Xuezhi, Zhang, Shucai, Liu, Yunpeng, Wang, Lin, Chen, Jianhua, Hu, Yi, Hang, Xiaosheng, Li, Juan, Liu, Chunling, Zhang, Yiping, Wang, Zhehai, Hu, Yanping, Gu, Kangsheng, Huang, Jian’an, Zhang, Liangming, Shan, Jinlu, Ouyang, Weiwei, Zhao, Yanqiu, Zhuang, Wu, Yu, Yan, Zhao, Jun, Zhang, Helong, Lu, Pei, Li, Weidong, Si, Meimei, Ge, Mingjing, Geng, Huaize
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795197/
https://www.ncbi.nlm.nih.gov/pubmed/35087031
http://dx.doi.org/10.1038/s41392-021-00841-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795197/
https://www.ncbi.nlm.nih.gov/pubmed/35087031
http://dx.doi.org/10.1038/s41392-021-00841-8

Ejemplares similares